Evidence map›Paper›PMID 33743555›Full record

ArticleCancer science2021

The effect of interleukin-17F on vasculogenic mimicry in oral tongue squamous cell carcinoma.

Rabeia Almahmoudi, Abdelhakim Salem, Elin Hadler-Olsen, Gunbjørg Svineng, Tuula Salo, Ahmed Al-Samadi

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Trends in immunotherapy for oral squamous cell carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023
    Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Rabeia AlmahmoudiDepartment of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-5336-7258
Abdelhakim SalemDepartment of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-9455-3823
Elin Hadler-OlsenDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Gunbjørg SvinengDepartment of Medical Biology, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Tuula SaloDepartment of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.
Ahmed Al-SamadiDepartment of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0003-1938-2136
University of Helsinki · FINorthern Norway Regional Health Authority · NOUiT The Arctic University of Norway · NO

Funding

the Cancer Society of Finlandthe Doctoral Program in Clinical Research (KLTO), Faculty of Medicine, University of Helsinkithe Emil Aaltonen Foundationthe Jane and Aatos Erkko Foundationthe Minerva Foundation of Medical Researchthe Sigrid Jusélius Foundation
6 · The paper itself

Abstract

Oral tongue squamous cell carcinoma (OTSCC) is one of the most common cancers worldwide and is characterized by early metastasis and poor prognosis. Recently, we reported that extracellular interleukin-17F (IL-17F) correlates with better disease-specific survival in OTSCC patients and has promising anticancer effects in vitro. Vasculogenic mimicry (VM) is the formation of an alternative vasculogenic system by aggressive tumor cells, which is implicated in treatment failure and poor survival of cancer patients. We sought to confirm the formation of VM in OTSCC and to investigate the effect of IL-17F on VM formation. Here, we showed that highly invasive OTSCC cells (HSC-3 and SAS) form tube-like VM on Matrigel similar to those formed by human umbilical vein endothelial cells. Interestingly, the less invasive cells (SCC-25) did not form any VM structures. Droplet-digital PCR, FACS, and immunofluorescence staining revealed the presence of CD31 mRNA and protein in OTSCC cells. Additionally, in a mouse orthotopic model, HSC-3 cells expressed VE-cadherin (CD144) but lacked Von Willebrand Factor. We identified different patterns of VM structures in patient samples and in an orthotopic OTSCC mouse model. Similar to the effect produced by the antiangiogenic drug sorafenib, IL-17F inhibited the formation of VM structures in vitro by HSC-3 and reduced almost all VM-related parameters. In conclusion, our findings indicate the presence of VM in OTSCC and the antitumorigenic effect of IL-17F through its effect on the VM. Therefore, targeting IL-17F or its regulatory pathways may lead to promising therapeutic strategies in patients with OTSCC.

Indexed as

Angiogenesis InhibitorsAnimalsAntigens, CDCadherin 5CadherinsCell Line, TumorHumansHuman Umbilical Vein Endothelial CellsInterleukin-17MiceNeovascularization, PathologicPlatelet Endothelial Cell Adhesion Molecule-1Squamous Cell Carcinoma of Head and NeckTongue NeoplasmsAngiogenesis InhibitorsAntigens, CDCadherin 5CadherinsIL17F protein, humanInterleukin-17PECAM1 protein, humanPlatelet Endothelial Cell Adhesion Molecule-1AngiogenesisCD31Interleukin-17FOral tongue squamous cell carcinomaVasculogenic mimicry

Identifiers

PMID33743555
PMCPMC8177764
OpenAlexW3136884856

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.